Lamictal. Buy more. Save more.

For full reports, see attachment
LONDON, Oct. 22, 2008-Chief Executive Officer’s Review: We are managing a considerable transition to our product portfolio this year as several mature pharmaceutical brands encounter generic competition in the USA. In the short-term, this is having a significant impact on pharmaceutical sales, although we continue to see good growth from other areas of the pharmaceuticals portfolio, including a recent improvement in prescription volumes for Adv…